All In MedTech

Device Trial Radar · NCT07700927

Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection

Acute Management of PJI With Local Implant Retention and Antibiotics Using the Sola2 AMF Knee System: A Multicenter Double-blind Clinical Trial.

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Aug 2028

Study completion Aug 2029

Sponsor

Lead sponsor
Solenic Medical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jul 14, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether the Sola2 AMF Knee System, when added to surgery and antibiotic treatment, can safely improve outcomes, knee function, and quality of life in adults with knee implant infection. The main questions this study aims to answer are: 1. Whether adding the Sola2 AMF Knee System improves knee function and quality of life at 6 months. 2. Whether adding the Sola2 AMF Knee System to surgery and antibiotic treatment affects the need for additional infection-related surgery. 3. Whether the Sola2 AMF Knee System can be used safely, based on device-related adverse events through 12 months. This study has two stages. In Stage 1, participants will be enrolled into sequential sentinel groups at increasing AMF temperature levels. All sentinel participants will receive active Sola2 AMF treatment. A safety review will occur after each sentinel group before proceeding to the next group. In Stage 2, researchers will compare participants who receive active Sola2 AMF treatment to participants who receive sham AMF treatment. All participants will receive surgery called debridement, antibiotics, and implant retention (DAIR), and antibiotic treatment for knee implant infection. Participants will: * Have DAIR surgery for knee implant infection; * Receive pathogen-appropriate antibiotic treatment from the study doctor; * If enrolled in Stage 1, receive active Sola2 AMF treatment at the designated sentinel temperature level; * If enrolled in Stage 2, receive either active Sola2 AMF treatment or sham AMF treatment, depending on randomization assignment; and * Complete follow-up visits and assessments for safety, infection status, pain, knee function, x-rays, laboratory tests, and other study-related outcomes.

Conditions

  • Prosthetic Joint Infection of Knee

Interventions

  • Intervention 1: Alternating Magnetic Field TreatmentDevice

    Active alternating magnetic field treatment is delivered using the investigational Sola2 AMF Knee System. The system is an external, non-contacting device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces. Treatment is administered in the operating room in conjunction with DAIR.

  • Intervention 2 - Sham TreatmentDevice

    Sham alternating magnetic field treatment is delivered during the randomized stage using the Sola2 AMF Knee System workflow. The sham treatment uses the same treatment timing and device-use steps as active treatment, without delivery of active alternating magnetic field energy

  • Debridement, Antibiotics, Implant RetentionProcedure

    Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants. In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Knee Injury and Osteoarthritis Outcome Score for Joint ReplacementTime frame: Baseline to 6 months
  2. Incidence of Infection-Related Surgical ReinterventionTime frame: From the index DAIR procedure through the primary efficacy analysis, triggered when 24 adjudicated events have occurred and at least 100 participants have completed 12-month follow-up
  3. Incidence of AMF Study Device-Related Adverse EventsTime frame: Through 12 months post-procedure

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Mount Carmel New Albany Surgical Hospital (JIS Orthopedics)

    New Albany, Ohio · Recruiting

  • Oklahoma Surgical Hospital

    Tulsa, Oklahoma · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.